Andreessen Horowitz
Listed as “Elegen”
- First observed:
- 29 Oct 2026
- Investment announced:
- Date not recorded
Elegen
Company website description: Skip cloning with the only entirely cell-free DNA synthesis provider. Sequences up to 7 kb. Error rates as low as 1:70,000/bp. Manufactured in USA, NGS-verified…
- Industry
- Bio + Health
- Tracked VC backers
- 1
- Source category
Bio + Health
Category source ↗Checked
Tracking coverage and points
Tracking coverage
A source check is on hold. Previous evidence is retained.
- Momentum +1 · Limited coverage
- The latest public index does not report a rank for this company.Index checked:
- Fundraising +2 · Awaiting data
- No verified dated source evidence recorded.
- New VC +3 · Awaiting data
- No verified dated source evidence recorded.
- Completed exit +10 · Source check held
- Latest source check was held; no new exit evidence was confirmed.
Coverage describes public evidence. Points require a qualifying milestone after your pick.
Publicly documented VC backing
These sources establish that the firm lists the company. The observation date records when RiseFinder captured the relationship; it does not establish when the investment happened.
Dated public activity
No dated funding or investment events are recorded yet. Initial portfolio listings establish the starting baseline and earn no points.